Our previous findings further indicate that breast cancer patients with elevated levels of SYCP2 exhibit increased resistance to DNA damage response (DDR) drug treatments, reinforcing SYCP2’s role as a key player in DDR-targeted therapy resistance [7]. Here, SYCP2 is linked to breast carcinoma.